PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Mol Cancer Ther. Author manuscript; available in PMC 2010 December 1.
Published in final edited form as:
PMCID: PMC2909540
NIHMSID: NIHMS202007

Effect of pazopanib on tumor microenvironment and liposome delivery

Abstract

Pathological angiogenesis creates an abnormal microenvironment in solid tumors, characterized by elevated interstitial fluid pressure (IFP) and hypoxia. Emerging theories suggest that judicious downregulation of pro-angiogenic signaling pathways may transiently “normalize” the vascular bed, making it more suitable for drug delivery and radiotherapy. In this work, we investigate the role of pazopanib, a small-molecule inhibitor of vascular endothelial growth factor (VEGF) receptors and platelet-derived growth factor (PDGF) receptors, on tumor IFP, angiogenesis, hypoxia, and liposomal drug delivery. Nude mice bearing A549 human non-small cell lung cancer xenografts were treated with pazopanib 100mg/kg (n=20) or vehicle (n=20) via oral gavage for 8 days, followed by a one-time intravenous dose of Doxil 10mg/kg (liposomal doxorubicin). Pazopanib treatment resulted in significant reduction of tumor IFP and decreased vessel density, assessed by CD-31 staining. Despite these trends towards normalization, high performance liquid chromatography (HPLC) revealed no differences in doxorubicin concentration between pazopanib-treated and control tumors, with Doxil penetration from microvessels being significantly reduced in the pazopanib group. Additionally, tumor hypoxia, evaluated by CA-IX immunostaining, and confirmed in a second study by EF5 expression (n=4 pazopanib 100mg/kg, n=4 vehicle), was increased in pazopanib-treated tumors. Our results suggest that the classical definition of tumor “normalization” may undermine the crucial role of vessel permeability and oncotic pressure gradients in liposomal drug delivery, and further that functional measures of normalization, such as reduced IFP and hypoxia, may not occur in parallel temporal windows.

Keywords: Pazopanib, interstitial fluid pressure, tumor microenvironment

INTRODUCTION

Solid tumors possess a variety of physiological abnormalities that pose a barrier for conventional non-surgical therapies (1). Aberrant angiogenesis drives new vessel sprouting, resulting in poorly organized vessel architecture. Tumor-associated vascular networks are haphazard and heterogeneous, exhibiting tortuous branching and arteriolar-venous shunting (2, 3). Endothelial cell tight junctions and pericytes are oftentimes absent, leading to loss of vessel integrity and leakage of plasma oncotic contents into the interstitial space. Additionally, the extracellular matrix (ECM) of tumors is reactive and contractile, supporting vascular proliferation and exerting mechanical stress on blood vessels to further compromise perfusion (2). Collectively, these characteristics create an abnormal tumor microenvironment characterized by hypoxia and elevated interstitial fluid pressure (IFP), factors thought to predispose to reduced chemosensitivity and radiosensitivity (4).

Elevations in IFP result in reduction of transvascular hydrostatic pressure gradients. This impedes the ability of systemic therapies, particularly macromolecules and liposomes, which rely on convection for transvascular transport, to traverse the endothelial barrier and penetrate the interstitium (4, 5). Studies suggest that reduction in IFP may be associated with improved delivery of chemotherapeutics and treatment response (6-8). However, also important to extravasation of liposomes is vascular permeability, or endothelial pore-size. By virtue of vessel hyperpermeability, liposomes and macromolecules preferentially accumulate in tumor tissue, sparing healthy tissue from excessive drug exposure (9-12).

The concept of vessel normalization was originally observed by Le Serve and Hellman, who noted that tumors treated with ICRF-159 (topoisomerase II inhibitor) exhibited more organized vessel architecture than untreated tumors, lending way to the idea that these morphological changes in vasculature may affect blood flow and drug delivery (3). In recent years, attention has turned to the use of anti-angiogenic agents as a means to normalize the tumor microenvironment (13-18). Jain proposes that judicious attenuation of pro-angiogenic signaling, within in a dose and time-dependent window period, may selectively prune immature blood vessels and remodel others. The resultant vasculature is less chaotic with greater pericyte coverage and less permeability, resembling that of normal tissue (4). These structural transformations are further thought to be accompanied by physiologic normalization parameters, such as decreased IFP and improved tumor oxygenation, factors thought to make the overall vascular network better suited for drug delivery and/or radiotherapy (4, 19). Notably, the normalization effect is transient and finite, as prolonged exposure to anti-angiogenic agents creates vascular regression, which can compromise drug delivery (14, 18).

While VEGF is the principal promoter of neovascularization, small-molecule tyrosine kinase inhibitors that have a broader spectrum of activity against other angiogenic signaling molecules have demonstrated successful clinical outcomes(20). However, few studies have investigated these agents in the context of the normalization phenomena. In this work, we investigate pazopanib, a novel second generation multitargeted inhibitor of VEGF receptor-1, -2, and -3 (VEGFR-1,-2,-3), PDGF receptor-α and –β (PDGFR-α, -β), and c-kit. Preclinical and clinical studies have revealed anti-angiogenic and anti-tumor activity in various cancers, and Phase II and III trials are ongoing (21-24). We examine the effect of pazopanib on tumor microenvironment in A549 human non-small cell lung cancer (NSCLC) xenografts. NSCLC exhibits elevated IFP and overexpresses PDGF, making it a suitable model for this study (8, 25). Further, the clinical treatment response to single-agent therapy is particularly poor for NSCLC, making normalization an attractive strategy to improve drug delivery or enhance other adjuvant regimens (26). We present preclinical data regarding the effect of pazopanib on tumor vasculature, and also provide insight into its functional effects on IFP, oxygenation, and liposomal drug delivery.

MATERIALS AND METHODS

Pharmaceuticals

Pazopanib (GW786034B), benzenesulfonamide,5-[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-monohydrochloride, was supplied by GlaxoSmithKline in powder form. Per the manufacturer’s instructions, the powder was suspended in vehicle (0.5% hydroxypropylemethylcellulose, 0.1% Tween-80 in distilled water, pH adjusted to 1.3-1.5 with 0.1N hydrochloric acid) to yield a concentration of 10mg/mL. Doxil (liposomal doxorubicin, Centocor Ortho Biotech Inc.) was purchased from the Duke Hospital pharmacy at a concentration of 2mg/mL.

Human NSCLC xenografts

A549 cells were purchased from American Type Culture Collection (ATCC). Per the cell bank, cells were verified via short-tandem repeat (STR) DNA profiling. Cells were cultured in Kaighn’s F-12 media (Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen) and 1% penicillin-streptamycin (Sigma-Aldrich). Adult female nude mice were injected in the right dorsal flank with 1 × 106 cells, suspended in 1:2 (v/v) PBS:Matrigel (BD Pharmaceuticals). Animal weights and tumor volumes (V=L x W2 x π/6) were measured every other day. All mice were housed in an isolated animal facility with free access to food and water. All procedures were approved and performed in accordance with the Institutional Animal Care and Use Committee (IACUC) guidelines.

Treatment regimen

Therapy was initiated when tumors reached a volume above 350mm3. Mice were randomized to receive pazopanib 100mg/kg (n = 20) or vehicle control (n = 20), both delivered via oral gavage. Mice were treated daily for eight days. Following the last administration of pazopanib or vehicle, all mice received a single dose of Doxil (liposomal doxorubicin) at 10mg/kg, via intravenous (i.v.) tail vein injection. Animals were sacrificed with a lethal pentobarbitol dose (250mg/kg) 24 hours after Doxil administration, in accordance with the half-life of Doxil in mice and the time of maximal tumor accumulation (12, 27). Tumors were excised, snap frozen over liquid nitrogen, and stored at −80°C.

A second smaller study (n = 4 control, n = 4 pazopanib 100mg/kg) was carried out to confirm hypoxia trends, as assessed by the endogenous hypoxia inducible factor-1 (HIF-1) regulated protein, CA-IX. This study was identical in design to the previous, the only difference being that three hours prior to sacrifice mice received an intraperitoneal (i.p.) injection of 80 mg/kg EF5 (2-(2-nitro-1H-imidazole-1-yl)-N-(2,2,3,3,3-pentafluoropropyl acetamide)), a marker that binds to areas of tissue hypoxia. EF5 was generously provided by Dr. Cameron Koch (University of Pennsylvania).

Tumor IFP measurement

On the day of sacrifice, tumor IFP measurements were made with a needle probe pressure monitor (Intra-Compartmental Pressure Monitor System, Stryker), fitted with an 18-gauge side-ported needle (Stryker) and connected to a syringe filled with 0.9% saline. Mice were anesthetized with isoflurane. The needle probe was inserted into the center of the tumor. IFP was recorded when the measurement stabilized. Normal muscle IFP was also measured. Tumor IFP values were normalized to muscle IFP (normalized IFP = tumor IFP/muscle IFP), and normalized IFP values were compared.

Immunohistochemistry

Half of the tumors from the first study (n = 10 control, n = 9 pazopanib 100mg/kg) were cut into 10μm sections using a LEICA CM 1850 cryotome (Meyer Instruments Incorporated, Houston TX) maintained at −24 to −28°C. 2-3 sections per tumor were stained for vasculature using anti-CD-31 (cell adhesion molecule on endothelial cells). Pericyte coverage was assessed by two markers, α-smooth muscle actin (α-SMA) and NG2. Serial sections were stained with an antibody against CA-IX, an endogenous hypoxia marker. Tumors injected with EF5 were also sectioned and immunostained to detect EF5 binding. Unless otherwise stated, sections were fixed in cold methanol (stored at −20°C) for 30 minutes, followed by blocking for 30 minutes at room temperature with 10% donkey serum (Jackson Immunoresearch). Sections were incubated with primary antibodies, followed by incubation with a fluorescent-conjugated secondary antibody, where applicable. All antibodies were diluted in PBS and incubated at room temperature, unless otherwise specified. Samples were rinsed with PBS three times for 5 minutes each between every consecutive step. All staining procedures ended with a 5 minute application of Hoechst 33342 (Sigma-Aldrich) to counterstain for cellular nuclei. Stained slides were stored in 4% paraformaldehyde at 4°C. Exclusion of a primary antibody served as a negative control. Marker specific protocols are described below.

CD-31, α-SMA, and NG2

Sections were incubated for 1 hour with rat anti-mouse CD-31 antibody (BD Biosciences), diluted 1:100, followed by incubation with a donkey anti-rat fluorescent secondary antibody (Alexa Fluor® 488, Invitrogen), diluted 1:1000. Pericyte coverage was assessed by α-SMA and NG2 immunostaining. Cy3-conjugated mouse monoclonal anti-α-SMA (Sigma-Aldrich) was applied at 1:400 dilution for 1 hour. For NG2 staining, slides were fixed in cold acetone at 4°C for 20 minutes instead of methanol. Slides were incubated overnight at 4°C with mouse anti-NG2 (Millipore), diluted 1:200, followed by application of a fluorescent donkey anti-mouse antibody (DyLight 459, Jackson Immunoresesearch) at 1:1000 for 1 hour. For NG2 staining, PBS with 0.2% tween (PBST), instead of PBS, was used for washings between steps.

CA-IX

Slides were fixed in acetone for 20 minutes, dried, and blocked for 30 minutes with primary antibody dilution buffer (PADB, Biomeda). Subsequently, slides were incubated for 1 hour with rabbit polyclonal antibody to CA-IX (Abcam), diluted 1:50 in PADB. Lastly, Cy2-conjugated donkey anti-rabbit antibody (Jackson Immunoresearch), diluted 1:150, was applied for 30 minutes.

EF5

EF5 was visualized with a Cy3-conjugated mouse monoclonal ELK3-51 antibody (Jackson Immunoresearch), applied for 1 hour at 1:1000.

Microscopy

Sections were imaged using a high-resolution solid-state camera mounted on a fluorescent microscope (Axioscop Zplus, Carl Zeiss Inc., Germany). Hoescht 33342 was detected using a DAPI filter. Doxil fluorescence and Cy3 signals were detected with a TRITC filter. CD-31 staining and Cy2 signals were detected with a FITC filter. A computer-controlled motorized stepping stage (Metamorph Imaging System, Molecular Devices Corporation) was used to automatically tile individual fields and generate up to three composite images of every tissue section. NG2 images were captured at 5x magnification. All other images were captured at 10x magnification in 16-bit monochrome signal depth. Fixed exposure times were preselected for each fluorochrome. To ensure that Doxil was not washed out during sample preparation, it was imaged first and then stained for CD-31.

Image analysis

The nuclear counterstain permitted region of interest (ROI) contour lines to be drawn around each tumor, and also allowed delineation and exclusion of necrotic areas, based on the absence of cellular nuclei. Mean vessel density (MVD) was determined for each section by overlaying a fixed grid over the image (Adobe Photoshop CS2), and manually counting CD-31-positive structures within 5 random viable fields to obtain a mean value for each tumor section. Within these fields, CD-31 staining was co-localized with α-SMA and NG2 staining, and the number of vessels that stained positive for these markers was determined. This latter number was divided by the total vessels in the field to determine the proportion of vessels exhibiting pericyte coverage. To quantify hypoxia, Image J (Image J, U. S. National Institutes of Health, http://rsb.info.nih.gov/ij/) was used to set a single optimal threshold value for both CA-IX and EF5. The amount of positively stained area was divided by the total tumor area to obtain area fraction of CA-IX and EF5 expression. For the purposes of presentation only, images were colored and adjusted for brightness and contrast.

Doxil penetration analysis

A previously described MATLAB algorithm was used to calculate the penetration distance of Doxil from vasculature (11, 28). Briefly, an ROI mask was defined that encompassed only the tumor and excluded artifact or necrosis. The mask was applied to CD-31 and Doxil images of each slide. CD-31 images were thresholded using Otsu’s method to identify vessels. After speckle noise was removed, a distance transform was performed on each of the CD-31 images, resulting in images whose pixel values represent distances to nearest blood vessel. All of the tumor pixels were sorted into bins (bin width = 0.75μm) of increasing distance from vasculature. Average intensity of Doxil fluorescence was calculated in each distance bin. Doxil penetration was defined as the average distance at which background-adjusted average doxorubicin fluorescence decreased to 50% of its maximum value in each section. These values were obtained from interpolation of fluorescence versus distance to nearest vascular surface in each slide. Distance to the center of each distance bin is reported.

High performance liquid chromatography

Tumors from the first study (n = 10 control, n = 9 pazopanib 100mg/kg) were quantified for total tumor doxorubicin concentration with HPLC. Tumors were quartered and one-fourth of each tumor was used for HPLC, as previously described (29). Briefly, samples were cryo-crushed in liquid nitrogen, thawed, and homogenized. Doxorubicin was extracted using chloroform/isopropanol (4/1), and sodium tetraborate (Sigma-Aldrich). Solvents in the organic layer were removed via nitrogen stream and reconstituted in methanol, followed by centrifugation and filtration of the supernatant. Tumor doxorubicin concentration was determined with HPLC-fluorescence readings of the supernatant. The HPLC readings were converted to doxorubicin concentration using a standard calibration curve that was generated using homogenized non-treated tumor tissue, spiked with known concentrations of doxorubicin (Sigma-Aldrich).

Determination of VEGF-R2 and PDGFR-ß receptor status

Tumors were homogenized and protein concentration quantified by the Bradford method. For phosphorylated protein determination, homogenized samples (100 μg) were subjected to SDS-PAGE on 4-20% gradient gels (Novex Incorporated), transferred to nitrocellulose membranes, and probed using primary antibodies against phosphorylated VEGFR-2 (Santa Cruz) and phosphophorylated PDGFR-ß (Cell Signaling Technology). Visualization was performed using the appropriate fluorescent-labeled secondary antibody [Alexa Fluor® 680 (Invitrogen) and IRDye800 (Rockland Incorporated)] and analyzed using the Odyssey Imaging system (Li-Cor Biosciences).

Total VEGFR-2 and PDGFR-ß levels were determined using the Meso Scale Discover system (MSD, Gaithersburg, Maryland). Uncoated Multi-array™ 96-well plates were incubated overnight with 50μl of capture antibody to VEGFR-2 or PDGFR-ß (Cell Signaling Technology) in TBS at 4°C. The antibody solution was removed and the plate blocked with 3% Blocker A/TBS for 1 hour at room temperature. Plates were washed with 0.05% Tween/TBS prior to addition of 50μg tumor homogenate. Plates were incubated at room temperature for 2 hours and washed with 0.05% Tween/TBS. Biotinylated detection antibody (R&D Systems) and labeled streptavidin (SULFO-TAG, MSD) was added to each well and incubated at room temperature for 1 hour. MSD Read Buffer was added and plates analyzed with a SECTOR Imager 2400 (MSD) according to manufacturer’s specifications.

Statistics

Statistical analysis was carried out using JMP 8.0 (SAS Institute Incorporated). Descriptive statistics are presented as mean ± SEM. One-way ANOVA was used to compare differences in tumor volumes between groups. The paired t-test was used to compare day-to-day animal weights. To avoid assumptions of a normal distribution, non-parametric tests were used for all other analyses. The Wilcoxon test was used to compare differences between groups. Spearman’s ranks correlation coefficient (ρ coefficient) was used to examine the relationship between two variables. P < 0.05 was considered statistically significant.

RESULTS

Response to treatment

Mice were randomized to receive pazopanib 100mg/kg (n = 20) or vehicle control (n = 20). The growth of A549 xenografts is shown in Figure 1. Tumors treated with pazopanib had smaller volumes at study completion, compared to control (720 ± 50mm3 control versus 570 ± 40mm3 pazopanib, P = 0.041). Mice experienced no significant weight changes, however two animals receiving pazopanib died prior to study completion from unknown causes.

Figure 1
Tumor volume response to pazopanib. Nude mice bearing A549 human non-small cell lung cancer xenografts (>350mm3) were randomized to receive daily oral administration of pazopanib 100mg/kg (n=18) or vehicle control (n=20), starting on day 0. Data ...

Drug distribution in pazopanib-untreated tumors

Distribution of drug with respect to vasculature and hypoxia in vehicle-treated tumors were analyzed as controls. Figures 2a-b show representative tri-color composite of control tumors, displaying Doxil (magenta) in relation to CD-31-stained vasculature (green) and hypoxic regions stained with CA-IX (yellow). Images show a high concentration of Doxil around the tumor periphery, with liposomes predominantly confined to perivascular spaces. Finally, many areas of vascularity lack surrounding Doxil and also overlay hypoxic areas. Nonetheless, nuclear counterstaining with Hoescht 33342 revealed viable tissue in these areas (not shown).

Figure 2
Representative tri-color composites of Doxil demonstrating the distribution of Doxil (magenta) in a control tumor, in relation to CD-31-stained blood vessels (green) and hypoxia (CA-IX yellow). A, Whole tumor section, 10x objective. B, Magnified view ...

Effect of pazopanib on angiogenesis

To assess the affect of pazopanib on vasculature, frozen sections were stained for CD-31. Consistent with the anti-angiogenic effects of pazopanib, MVD (vessels/mm2) was reduced in treated tumors (251 ± 19 control versus 101 ± 11 pazopanib, P < 0.0001) (Figures 3a, b). The proportion of pericyte-covered vessels, assessed by anti-α-SMA and anti-NG2 immunostaining, decreased in the treatment group (α-SMA: 0.84 ± 0.03 control versus 0.68 ± 0.05 pazopanib, P = 0.016; NG2: 0.72 ± 0.07 control versus 0.26 ± 0.04, P < 0.001) (Figures 3a, c-d).

Figure 3
Effect of pazopanib on vasculature and vessel pericyte coverage. A, Representative composite image of vessels (CD-31, green) and pericytes (α-SMA, red). B, Mean vessel density (MVD) determined by CD-31 staining. C, Vessel pericyte coverage determined ...

IFP and hypoxia trends

Tumor IFP was measured prior to sacrifice, and values were normalized to normal muscle IFP. Normalized tumor IFP was decreased in the pazopanib group (14.6 ± 1.9 control versus 7.6 ± 3.2 pazopanib, P = 0.015) (Figure 4a). IFP was positively correlated to MVD (Spearman’s ρ = 0.7667, P = 0.016) (Figure 4b).

Figure 4
Comparison of IFP and hypoxia markers in pazopanib and control tumors. A, Comparison of normalized tumor IFP measured at study end. Normalized tumor IFP = Tumor IFP/normal muscle IFP. Horizontal bars represent means. B, Correlation of normalized tumor ...

Animals treated with pazopanib showed increased hypoxia, as quantified by CA-IX immunostaining. As shown in Figure 4c, the percent area staining positive for CA-IX was higher in the pazopanib-treated group (7.0 ± 1.0% control versus 16.7 ± 1.7% pazopanib, P < 0.001). This increase in hypoxia was confirmed by EF5 binding. Consistent with CA-IX expression, the percent area staining positive for EF5 was higher for pazopanib-treated tumors (36.6 ± 4.6%) than control (16.0 ± 2.6%), P = 0.007 (Figure 4d).

Effect of pazopanib on Doxil delivery

To assess the effect of pazopanib pre-treatment on liposome delivery, mice received an i.v. injection of Doxil 10mg/kg following an eight-day treatment course with pazopanib 100mg/kg or vehicle control. 24 hours after Doxil administration, mice were sacrificed. As shown in Figure 5a, there was no significant difference in doxorubicin concentration between pazopanib-treated and control tumors (10.8 ± 1.8 ng/mg control versus 12.3 ± 1.0 ng/mg pazopanib, P = 0.596). A custom MATLAB algorithm was used to determine the fluorescence intensity of Doxil as a function of distance from the nearest microvessel. These data are presented in Figure 5b. Doxil penetration, defined as the distance from the nearest vessel at which Doxil fluorescence dropped to 50% of its maximum, was decreased in tumors treated with pazopanib (7.7 ± 0.4μm control versus 3.4 ± 0.7μm pazopanib, P = 0.024) (Figure 5c).

Figure 5
Effect of pazopanib on Doxil delivery. Animals were treated with pazopanib 100mg/kg or vehicle control for 8 days, followed by a one-time dose of intravenous Doxil 10mg/kg. A, HPLC analysis of tumor doxorubicin concentration (ng of doxorubicin/mg of tumor ...

Effect of pazopanib on VEGFR-2 and PDGFR-ß

Phosphorylated and total levels of VEGFR-2 and PDGFR-ß were determined via quantitative Western blotting and a plate-based antibody capture assay, respectively. Total receptor levels were significantly decreased in the pazopanib-treated group (VEGFR-2, P = 0.018; PDGFR-ß, P = 0.003) (Figures 6a-b). Though not statistically significant, phosphorylation of PDGFR-ß trended upward.

Figure 6
Total and phosphorylated levels of VEGF-R2 and PDGFR-ß. A plate-based antibody capture assay (Meso Scale Discovery platform) was used to quantify total receptor levels in vehicle-treated control tumors and pazopanib-treated tumors. Phosphorylated ...

DISCUSSION

It has been reported that tumor-associated neovascularization results in an abnormal tumor microenvironment that is unsuitable for drug delivery (4). Composite images of CD-31, CA-IX, and Doxil (Figure 2) confirm a number of unique tumor pathophysiologies. Despite an abundance of vasculature, a notable amount of tissue is hypoxic, suggesting the vascular bed is inefficient for nutrient and oxygen transport. Reasons for these insufficiencies are multifactorial and go beyond high tissue oxygen consumption, to include vascular characteristics such as inefficient vessel architecture or vessel density, diversion from shunt flow, and inadequate intravascular partial pressure of oxygen (pO2) (30). These vessel abnormalities are reflected in the spatial distribution of drug delivery. A dominant feature of Figure 2 is the apparent lack of Doxil surrounding a number of blood vessels, particularly those vessels that coincide with areas of poor oxygenation. This is suggestive of regionally poor transport and functionally abnormal vasculature, though could also reflect regions of low liposome extravasation or spatial differences in vascular permeability. Consistent with previous studies, our results demonstrate that liposomes preferentially accumulate in the perivascular space (9, 31). This limited distribution is partially explained by elevated tumor IFP, which may reduce the convective fluxes that macromolecules (>10kDa) rely on for transport into the interstitium (1, 32). The interstitial space poses yet another challenge for drug delivery, as cytokines and growth factors, notably PDGF, promote integrin-fibroblast interactions, creating stromal tension and IFP elevation (33). Such interactions also lend way to small ECM pore size and limited interconnectedness, thereby decreasing the available volume fraction for molecule transport (34). Increased solid stress from cellular proliferation may also play a role in tumor IFP elevation (35). IFP is thought to be uniformly elevated throughout the tumor mass, dropping steeply at the tumor periphery, where perfusion is also greatest (32, 36, 37). Accordingly, our results show that Doxil distribution is limited largely to the tumor periphery.

We demonstrate that modulation of VEGF and PDGF receptor signaling with pazopanib alters aspects of the tumor microenvironment in NSCLC xenografts. Elevated IFP is a hallmark of solid tumor microenvironment (5, 19). While intra-/extra-vascular compartmental pressures and transvascular fluid flux are meticulously maintained in normal tissues by functional lymphatics, vessel integrity, ECM interactions, and Starling forces, tumors lack such regulation (5, 32). A number of studies have noted reduction of IFP with selective inhibition of VEGFR or PDGFR (15-17, 38). However, few studies have examined the role of combination VEGFR/PDGFR blockade on tumor IFP (39, 40). Our results demonstrate that pazopanib, a tyrosine kinase receptor inhibitor of VEGR and PDGFR, causes a decrease in tumor IFP (Figure 4a). IFP is also positively correlated with MVD (Figure 4b), implying that vascular regression contributes to IFP reduction. VEGF is known to drive proliferation of immature, hyperpermeable blood vessels (41-43). Genetic deletion of VEGF or pharmacological inhibition of VEGFR-2 signaling has been shown to selectively ablate immature vasculature, namely those that vessels lack pericyte coverage (14, 42, 44). Our results show a significant reduction in MVD in pazopanib-treated tumors (Figures 3a, b). We postulate that pazopanib-mediated VEGFR inhibition causes at least partial regression of leaky vasculature with overall reduction in vascular permeability. The result is reduced extravasation of plasma oncotic particles with subsequent decrease in associated transvascular fluid flux.

Pazopanib-mediated PDGFR inhibition also likely plays a role in decreasing IFP. Inhibition of this receptor not only decreases pericyte-mediated angiogenesis, but downregulates the recruitment and function of fibroblasts and stromal cells (16, 32, 33, 42). As A459 also expresses PDGFR, decreased tumor cell proliferation may also be expected (35, 45). This anti-cellular effect, along with the stromal relaxation effects of PDGFR inhibition may contribute to decreased solid stress and interstitial pressure.

Despite IFP reduction, tumors treated with pazopanib exhibited decreased Doxil penetration, compared to control (Figure 5c). This is in discord with the classic normalization hypothesis that would suggest overall improved delivery. In one exemplary study of normalization, treatment with anti-VEGF reduced tumor IFP, presumably through selective pruning of leaky vasculature and decrease in vessel permeability (15). Anti-VEGF treated tumors also exhibited deeper intra-tumor penetration of BSA molecules, emphasizing the benefits of an induced hydrostatic pressure gradient in transvascular convection. Notably though, BSA has a diameter of 7nm, far smaller than liposomes (Doxil diameter ~100nm) or tumor endothelial pores, which have been reported to be at least 400nm (10). This size difference is important when considering that a decrease in vessel permeability may not compromise BSA transport, and in fact that a drop in vascular permeability with associated restoration of transcapillary pressures may indeed increase extravasation of molecules this size by simple virtue of favorable pressure gradients. However, simply decreasing IFP overlooks the influence of vessel permeability and oncotic pressure gradients in particle transport.

Liposomes and macromolecular drug delivery systems rely on vessel hyperpermeability for trans-endothelial transport, a phenomena coined the “enhanced permeability and retention” (EPR) effect (46). By this argument and as suggested by our results, decreasing vessel permeability, as a means to normalize vasculature, may serve to hinder intra-tumoral delivery of liposomes. In other words, reduction of vessel leakiness may not be entirely beneficial for liposome transport, as despite favorable hydrostatic pressure gradients, particles are less able to extravasate across structurally normalized vessels with reduced permeability. Further, decreasing vessel permeability serves to increase plasma oncotic pressure, providing yet another driving force for liposomes to remain in intravascular/perivascular areas. Although we used a doxorubicin containing liposome for this work, similar effects would be expected for any type of nanoparticle. It is important to acknowledge that Doxil penetration data was collected at a single time point in this investigation. Liposomes may continue to distribute after 24 hours, however maximum tumor accumulation has been show to occur at 24 hours (27).

MVD may influence the penetration of Doxil, as measured here, since a higher MVD provides more sources for Doxil to enter the tissue and penetrate the interstitium. However, our results show that the median distance from a tumor pixel to a vascular pixel is 18.8 ± 0.7μm for the control group and 31.2 ± 1.8μm for the pazopanib group (P < 0.001). As expected, the greater distance between a tumor pixel and a vascular pixel is consistent with a drop in MVD for the pazopanib group. Since these distances are much greater than the average penetration distances, it is doubtful that MVD influenced the reported penetration. Rather, the observed changes are likely dominated by permeability, convective flux, and the effective diffusion coefficient (32).

Though Doxil penetration was reduced with pazopanib pre-treatment, HPLC revealed no difference in tumor doxorubicin concentration between groups (Figure 5a). This is an intriguing observation, as MVD was decreased by >50% in pazopanib-treated tumors (Figure 3a, c). This supports the paradigm of the tumor vascular bed being a construct of two distinct vascular networks, immature and mature (44). It is likely the former vascular type, lacking in vessel integrity and function, that is most sensitive to VEGF-inhibition and therefore initially targeting by pazopanib (39, 42, 47). Hence, many of lost vessels may have been completely non-functional and therefore had no effect on overall amount of delivery. Also plausible, the overall reduction in intra-tumoral pressure may have altered blood flow in a way that positively compensated for vessel loss.

An unforeseen observation of this study was the increase in hypoxia in pazopanib-treated tumors (Figures 4c, d). Preliminary work done in this xenograft suggested improved oxygenation after eight days of pazopanib 100mg/kg (data not shown), providing justification for the dosing and duration of drug used in this study. However, our data are suggestive of excessive vessel regression with this treatment course. This trend of vascular regression is supported by increased expression of hypoxia markers, CA-IX and EF5, as well as histological analysis of pericytes stained with anti-α-SMA and NG2. As demonstrated in Figures 3c-d, the proportion of pericyte-coated vessels decreases with pazopanib administration. This is in accordance with pazopanib’s antagonism of PDGF-receptors. PDGF-receptor signaling is imperative for angiogenesis, as it triggers recruitment of fibroblasts and perivascular cells. These mural cells secrete cytokines to support vessel proliferation, and also provide structural and hemostatic control of nascent vessel sprouts to bring about vessel maturity (48). PDGF inhibition has been shown to decrease periendothelial cells, a trend that digresses from the structural features of vessel normalization (8, 47). Despite these effects, previous studies report decreased IFP, improved oxygenation, and enhanced cytotoxic drug delivery with PDGF-inhibitors such as Imatinib and Sunitinib (8, 16, 38, 39). This implicates that downregulation of PDGF signaling may contribute to functional vessel normalization, partially through blockade of pericyte-mediated angiogenesis. However, continuous exposure to pazopanib and other vessel-disrupting agents, likely destroys pericyte-endothelial cell interactions, ultimately compromising mature tumor vasculature and causing hypoxia (13, 39).

The finding of increased hypoxia reiterates the precise sensitivity of drug dosing and timing that is required for normalization to occur. Jain proposes a “normalization window,” wherein IFP is reduced and tumor oxygenation is improved. However, our results show that the fluctuations in these functional measures of normalization may not parallel one another. Whereas IFP may remain decreased for several days following the initiation of anti-VEGF therapy, improvements in oxygenation may be short-lived, as little as one day in some cases (13, 15, 18). Therefore, in contrast to previous studies that have utilized IFP as a primary marker of normalization, our data imply that the window of normalization may be better assessed by oxygenation status (4, 15, 39). This is reiterated by Cao, et al., who show that systemic overexpression of angiopoietin-2 (endothelial Tie-2 receptor agonist) causes significant vessel dropout with improved perfusion in remaining vessels (49). Despite the increase in perfusion, hypoxia was exacerbated, highlighting the delicate interplay between parameters such as vessel density and structure, blood flow, perfusion, and oxygenation. The dynamic nature of these parameters, along with the varying effects of dosing, timing, and type of vessel-targeting therapy, must be accounted for when considering normalization.

Also important, though largely overlooked by the normalization hypothesis, is the spatial and temporal heterogeneity of perfusion and hypoxia, as well as downstream signaling pathways that are activated by changes in hypoxia (30). Pertinent to this discussion, hypoxia may induce phosphorylation of PDGFR-ß and induce cell survival via a HIF-1α mediated pathway (50). Our results show a decrease in total levels of VEGFR-2 and PDGFR-ß with pazopanib, consistent with a decrease in endothelial cells and pericytes and/or stromal cells respectively, as well as overall tumor volume (Figure 1). Though phosphorylated levels of both receptor types were statistically unchanged, phosphorylation of PDGFR-ß seemingly trended upward, perhaps suggesting hypoxic receptor activation that may compete with pazopanib’s mechanism of action.

In conclusion, this investigation demonstrates that pazopanib exerts anti-vascular effects in NSCLC xenografts, and that concurrent VEGFR/PDGFR inhibition may be a useful approach to modulate and normalize the tumor microenvironment. VEGFR and PDGFR inhibition likely decrease IFP through at least two distinct mechanisms. The former causes a regression of dysfunctional, leaky vessels, with an associated decrease in interstitial colloid osmotic pressure, while anti-PDGFR activity likely hampers ECM interactions to loosen an otherwise stiff stroma. While the observed trends in IFP support the normalization hypothesis, the reduced penetration of liposomes in pazopanib-treated tumors suggests that the normalization phenomena undermines the EPR effect that is fundamental to liposome transport. Decreasing vessel permeability to restore transcapillary pressure gradients may be of questionable benefit for liposome extravasation. Finally, the finding of increased hypoxia and decreased pericyte coverage, suggesting destruction of mature vessels in pazopanib-treated tumors, underscores the seemingly transient nature of the normalization window. Though this investigation is limited by a single time point and anti-angiogenic agents have temporal effects on vasculature that are not studied here, the question of feasibility, particularly in the clinical setting, for achieving the precision in dosing and timing of drug delivery required for structural vessel normalization, while still remaining in a window that normalizes functional parameters like IFP and oxygenation, is debatable. Nonetheless, as more multitargeted anti-angiogenic agents emerge into clinical use, it will be of crucial importance to understand their dynamic role on tumor structure and function in order to achieve optimal anti-cancer effect.

ACKNOWLEDGEMENTS

The authors would like to thank Joseph Herbert for his assistance with animal work. This work was supported by a research contract from GlaxoSmithKline, as well as support from the Duke Cancer Center and the Howard Hughes Medical Institute.

Funding: GlaxoSmithKline, Howard Hughes Medical Institute, Duke Cancer Center

Abbreviations

NSCLC
Non-small cell lung cancer
IFP
Interstitial Fluid Pressure
VEGF/VEGFR
Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor Receptor
PDGF/PDGFR
Platelet Derived Growth Factor, Platelet Derived Growth Factor Receptor
HPLC
High Performance Liquid Chromatography
MVD
Mean Vessel Density
CA-IX
Carbonic Anhydrase IX
α-SMA
alpha-smooth muscle actin
BSA
bovine serum albumin

REFERENCES

1. Jain RK. Barriers to drug delivery in solid tumors. Sci Am. 1994;271:58–65. [PubMed]
2. Cairns R, Papandreou I, Denko N. Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res. 2006;4:61–70. [PubMed]
3. Le Serve AW, Hellmann K. Metastases and the normalization of tumour blood vessels by ICRF 159: a new type of drug action. Br Med J. 1972;1:597–601. [PMC free article] [PubMed]
4. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58–62. [PubMed]
5. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer. 2004;4:806–13. [PubMed]
6. Pietras K, Rubin K, Sjoblom T, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 2002;62:5476–84. [PubMed]
7. Salnikov AV, Iversen VV, Koisti M, et al. Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy. FASEB J. 2003;17:1756–8. [PubMed]
8. Vlahovic G, Ponce AM, Rabbani Z, et al. Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. Br J Cancer. 2007;97:735–40. [PMC free article] [PubMed]
9. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 1994;54:3352–6. [PubMed]
10. Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995;55:3752–6. [PubMed]
11. Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst. 2006;98:335–44. [PubMed]
12. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003;42:419–36. [PubMed]
13. Ansiaux R, Baudelet C, Jordan BF, et al. Mechanism of reoxygenation after antiangiogenic therapy using SU5416 and its importance for guiding combined antitumor therapy. Cancer Res. 2006;66:9698–704. [PubMed]
14. Dickson PV, Hamner JB, Sims TL, et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res. 2007;13:3942–50. [PubMed]
15. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004;64:3731–6. [PubMed]
16. Vlahovic G, Rabbani ZN, Herndon JE, 2nd, Dewhirst MW, Vujaskovic Z. Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation. Br J Cancer. 2006;95:1013–9. [PMC free article] [PubMed]
17. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10:145–7. [PMC free article] [PubMed]
18. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004;6:553–63. [PubMed]
19. Fukumura D, Jain RK. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res. 2007;74:72–84. [PMC free article] [PubMed]
20. Marx J. Cancer. Encouraging results for second-generation antiangiogenesis drugs. Science. 2005;308:1248–9. [PubMed]
21. Hurwitz HI, Dowlati A, Saini S, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res. 2009;15:4220–7. [PubMed]
22. Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther. 2007;6:2012–21. [PubMed]
23. Podar K, Tonon G, Sattler M, et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci U S A. 2006;103:19478–83. [PubMed]
24. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043) J Clin Oncol. 2009;27:3126–32. [PubMed]
25. Sause W, Kolesar P, Taylor SI, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest. 2000;117:358–64. [PubMed]
26. Lilenbaum RC, Herndon JE, 2nd, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730) J Clin Oncol. 2005;23:190–6. [PubMed]
27. Charrois GJ, Allen TM. Rate of biodistribution of STEALTH liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity. Biochim Biophys Acta. 2003;1609:102–8. [PubMed]
28. Moeller BJ, Dreher MR, Rabbani ZN, et al. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell. 2005;8:99–110. [PubMed]
29. Palmer GM, Boruta RJ, Viglianti BL, Lan L, Spasojevic I, Dewhirst MW. Non-invasive monitoring of intra-tumor drug concentration and therapeutic response using optical spectroscopy. J Control Release. 2010;142:457–64. [PMC free article] [PubMed]
30. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer. 2008;8:425–37. [PubMed]
31. Kong G, Braun RD, Dewhirst MW. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res. 2000;60:4440–5. [PubMed]
32. Bouzin C, Feron O. Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery. Drug Resist Updat. 2007;10:109–20. [PubMed]
33. Ostman A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev. 2004;15:275–86. [PubMed]
34. Yuan F, Krol A, Tong S. Available space and extracellular transport of macromolecules: effects of pore size and connectedness. Ann Biomed Eng. 2001;29:1150–8. [PubMed]
35. Sarntinoranont M, Rooney F, Ferrari M. Interstitial stress and fluid pressure within a growing tumor. Ann Biomed Eng. 2003;31:327–35. [PubMed]
36. Jain RK, Tong RT, Munn LL. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res. 2007;67:2729–35. [PMC free article] [PubMed]
37. Viglianti BL, Abraham SA, Michelich CR, et al. In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: illustration of targeted delivery. Magn Reson Med. 2004;51:1153–62. [PubMed]
38. Pietras K, Ostman A, Sjoquist M, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 2001;61:2929–34. [PubMed]
39. Zhou Q, Guo P, Gallo JM. Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin Cancer Res. 2008;14:1540–9. [PubMed]
40. Klosowska-Wardega A, Hasumi Y, Burmakin M, et al. Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma. PLoS One. 2009;4:e8149. [PMC free article] [PubMed]
41. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146:1029–39. [PubMed]
42. Greenberg JI, Shields DJ, Barillas SG, et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature. 2008;456:809–13. [PMC free article] [PubMed]
43. Rapisarda A, Melillo G. Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resist Updat. 2009;12:74–80. [PMC free article] [PubMed]
44. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest. 1999;103:159–65. [PMC free article] [PubMed]
45. Reinmuth N, Liersch R, Raedel M, et al. Combined anti-PDGFRalpha and PDGFRbeta targeting in non-small cell lung cancer. Int J Cancer. 2009;124:1535–44. [PubMed]
46. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65:271–84. [PubMed]
47. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003;111:1287–95. [PMC free article] [PubMed]
48. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6:389–95. [PubMed]
49. Cao Y, Sonveaux P, Liu S, et al. Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angiogenesis and tumor growth. Cancer Res. 2007;67:3835–44. [PubMed]
50. Zhang SX, Gozal D, Sachleben LR, Jr., Rane M, Klein JB, Gozal E. Hypoxia induces an autocrine-paracrine survival pathway via platelet-derived growth factor (PDGF)-B/PDGF-beta receptor/phosphatidylinositol 3-kinase/Akt signaling in RN46A neuronal cells. FASEB J. 2003;17:1709–11. [PubMed]